Page last updated: 2024-12-10

17-phenyltrinorprostaglandin e2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

17-phenyltrinorprostaglandin E2, often abbreviated as **17-PT-PGE2**, is a synthetic analog of prostaglandin E2 (PGE2). It's important for research due to its unique properties and potential applications in various fields.

Here's a breakdown of its significance:

**What it is:**

* **Prostaglandin Analog:** It's a synthetic compound structurally similar to naturally occurring prostaglandins, specifically PGE2.
* **Modifications:** Compared to PGE2, 17-PT-PGE2 has modifications at the 17th carbon, leading to a phenyl group instead of a hydroxyl group, and lacks the three carbons in the omega-chain.
* **Increased Stability:** These modifications result in a more stable compound with a longer half-life compared to PGE2.

**Importance in Research:**

* **Pharmacology:**
* **Longer Duration of Action:** Its extended half-life makes it a valuable tool for studying the effects of PGE2 over prolonged periods, offering insights into its pharmacological mechanisms.
* **Target Specificity:** Researchers can use it to study specific PGE2 receptor subtypes, as it may bind differently than natural PGE2.
* **Potential Therapeutic Applications:** Its stability and potential for targeted delivery make it a candidate for developing new drugs, particularly for treating inflammation, pain, and gastrointestinal disorders.
* **Biochemistry:**
* **Prostaglandin Synthesis and Metabolism:** Studying 17-PT-PGE2 helps researchers understand the pathways involved in prostaglandin synthesis and metabolism, which can be crucial for developing new therapies.
* **Cellular Signaling:** Its ability to interact with specific receptors can contribute to understanding how PGE2 influences cellular signaling and communication.

**Specific Research Areas:**

* **Cancer Research:** Studies have explored the potential of 17-PT-PGE2 for treating various cancers, particularly breast and prostate cancer, due to its effects on cell growth and proliferation.
* **Neurological Disorders:** Researchers are investigating its role in neuroinflammation and its potential as a therapeutic agent for conditions like Alzheimer's disease.
* **Cardiovascular Research:** 17-PT-PGE2 has been studied for its potential in regulating blood pressure and platelet aggregation, suggesting possible applications in cardiovascular medicine.

**Note:** 17-PT-PGE2 research is still ongoing, and its full therapeutic potential is yet to be fully established. Further studies are needed to assess its safety and efficacy in humans.

Overall, 17-PT-PGE2 is a valuable research tool with potential applications in various fields. Its stability, long half-life, and unique pharmacological properties make it a promising candidate for developing novel therapeutic strategies.

17-phenyltrinorprostaglandin E2: an EP1 receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

17-phenyl-18,19,20-trinor-prostaglandin E2 : A prostanoid that is 18,19,20-trinor-prostaglandin E2 in which one of the terminal methyl hydrogens has been replaced by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283068
CHEMBL ID1879970
CHEBI ID87820
SCHEMBL ID3367843
MeSH IDM0243903

Synonyms (48)

Synonym
BRD-K90214371-001-02-0
17-phenyl-pge2
gtpl1912
17-pt-pge2
17-ph-omega-trinor-pge2
17-phenyl-omega-trinor-prostaglandin e2
17-phenyl-omega-trinor-pge2
17-phenyl-trinor-prostaglandin e2
17-phenyl-trinor-pge2
LMFA03010067
9-oxo-11r,15s-dihydroxy-17-phenyl-18,19,20-trinor-5z,13e-prostadienoic acid
BSPBIO_001369
IDI1_033839
17-phenyl-trinor-pge..2..
NCGC00161300-01
NCGC00161300-02
NCGC00161300-03
17-phenyltrinorprostaglandin e2
17-ph-trinor-pge2
17-phenyl-omega-trinor pge2
HMS1989E11
17-phenyl trinor prostaglandin e2
BML2-B01
HMS1361E11
HMS1791E11
SCHEMBL3367843
pge2,17-phenyl
bdbm82094
cas_38315-43-4
(z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxy-5-phenylpent-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
17-phenyl-18,19,20-trinor-pge2
cl 116147
CHEBI:87820
17-phenyltrinor-prostaglandin e2
17-phenyl-18,19,20-trinor-prostaglandin e2
17-phenyltrinor-pge2
(5z)-7-{(1r,2r,3r)-3-hydroxy-2-[(1e,3s)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl}hept-5-enoic acid
CHEMBL1879970
FOBVMYJQWZOGGJ-XYRJXBATSA-N
9-oxo-11.alpha.,15s-dihydroxy-17-phenyl-18,19,20-trinor-prosta-5z,13e-dien-1-oic acid
HMS3402E11
HMS3648J13
DTXSID80274308
17-phenyl-18,19,20-trinorprostaglandin e2
Q27070789
SR-01000946438-1
sr-01000946438
PD021123
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
prostaglandin receptor agonistAn agonist that binds to and activates prostaglandin receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
prostanoidThe family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.
alicyclic ketoneA cyclic ketone in which the carbocyclic ring structure which may be saturated or unsaturated, but may not be a benzenoid or other aromatic system.
beta-hydroxy ketoneA ketone containing a hydroxy group on the beta-carbon relative to the C=O group.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
oxo monocarboxylic acidAny monocarboxylic acid having at least one additional oxo functional group.
hydroxy monocarboxylic acidAny monocarboxylic acid which also contains a separate (alcoholic or phenolic) hydroxy substituent.
olefinic compoundAny organic molecular entity that contains at least one C=C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency0.18890.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346396Rat EP3 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346318Rat EP2 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346345Rat EP1 receptor (Prostanoid receptors)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.
AID1346408Human EP1 receptor (Prostanoid receptors)2002The Journal of pharmacy and pharmacology, Apr, Volume: 54, Issue:4
Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques.
AID1346336Mouse EP3 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346372Mouse EP1 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (26.32)18.2507
2000's21 (55.26)29.6817
2010's6 (15.79)24.3611
2020's1 (2.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.79 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]